DOCM.SW DocMorris AG (SIX) up 5.16% on 10 Feb 2026: model flags 9.98% monthly upside

DOCM.SW stock led Swiss gainers on 10 Feb 2026, closing at CHF 5.91, up 5.16% as traders reacted to a short-term technical rebound. Volume reached 144,654 shares versus a 50-day average of 322,651, showing a smaller-than-normal participation. We see the move as a tactical bounce inside a longer downtrend from the year high CHF 24.90 to the current level. The intraday range was CHF 5.65–5.95 and the next catalyst is the earnings report scheduled for 19 Mar 2026. This piece examines drivers, ratios, technicals and Meyka AI forecasts for DOCM.SW stock on SIX in Switzerland.

DOCM.SW stock: market move and trading context

DOCM.SW stock closed at CHF 5.91, a +5.16% change on 10 Feb 2026, making it one of the top gainers on SIX that session. The rise came on 144,654 shares, below the average daily volume of 322,651, suggesting a selective rebound rather than broad buying.

The Healthcare sector on the Swiss market was positive today (sector 1D +1.96%), which likely supported demand for DocMorris AG shares. Investors noted the wide 52-week range (CHF 4.79–24.90) and the company’s upcoming earnings date 19 Mar 2026, a potential short-term catalyst. More company detail at DocMorris corporate site.

DOCM.SW stock: fundamentals snapshot

DocMorris AG shows a market cap of CHF 286,978,530 and EPS -4.58, producing a negative PE of -1.29. Revenue per share stands at CHF 36.41 and book value per share is CHF 16.47, while cash per share is CHF 7.89.

Key ratios point to mixed fundamentals: Price / Sales 0.27, Price / Book 0.36, Current Ratio 3.25, and Debt / Equity 0.65. These figures show solid liquidity but persistent negative profitability and operating cash flow weakness, relevant for DOCM.SW earnings and valuation discussions.

DOCM.SW stock: technicals and momentum signals

Technicals show a tactical upward tilt: RSI 58.98, MACD 0.22 with signal 0.15, and ADX 26.52 indicating a strengthening trend. The 50-day average price is CHF 5.79 and the 200-day average is CHF 6.93, so price sits near the 50-day but below the 200-day.

Volatility tools give context: ATR 0.32, Bollinger middle band CHF 5.78, upper CHF 6.49 and lower CHF 5.07. Momentum oscillators are neutral-to-positive, supporting the short-term gain while longer-term technicals remain cautious.

DOCM.SW stock: Meyka AI grade and model forecasts

Meyka AI rates DOCM.SW with a score out of 100: Score 64.11 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects stronger balance-sheet metrics but weak profitability and mixed sector signals.

Meyka AI’s forecast model projects a monthly target of CHF 6.50, implying +9.98% from the current CHF 5.91, and a quarterly target of CHF 16.47, implying +178.66%. Forecasts are model-based projections and not guarantees. See DocMorris LinkedIn for company updates DocMorris LinkedIn.

DOCM.SW stock: valuation view and price targets

Valuation mixes value and risk. Negative earnings produce a distorted PE (-1.29), while P/S 0.27 and P/B 0.36 suggest the market prices in distress. Enterprise value CHF 447,244,530 versus market cap CHF 286,978,530 highlights leverage in enterprise metrics.

For planning, we frame three scenarios: a conservative near-term target CHF 6.50, a base-case CHF 7.50 if margins recover, and a bull-case CHF 16.50 aligned with the quarterly model projection. These are model-led reference points, not firm recommendations.

DOCM.SW stock: risks and potential catalysts

Primary risks are continued negative profitability (net margin -11.38%, EPS -4.58), low average liquidity (avg volume 322,651), and regulatory or competitive pressure in online pharmacy markets. The company’s operating cash flow per share is -2.42 which raises free cash flow concerns.

Key catalysts include the 19 Mar 2026 earnings release, any positive margin guidance, cost reductions, or stronger online sales. The company’s cash buffer CHF 7.89 per share provides short-term runway, but any operational slip could pressure the stock further.

Final Thoughts

DOCM.SW stock closed the session on 10 Feb 2026 at CHF 5.91, up 5.16%, a short-term rebound on light volume. Fundamentals still show negative earnings (EPS -4.58) but solid liquidity (Current Ratio 3.25, cash per share CHF 7.89). Technicals point to a neutral-to-positive short-term setup with RSI 58.98 and MACD momentum. Meyka AI’s model projects CHF 6.50 as a one-month target (implied +9.98%) and a quarterly scenario of CHF 16.47 (implied +178.66%). Meyka AI provides this as an AI-powered market analysis platform; forecasts are model outputs, not guarantees. Investors should watch the 19 Mar 2026 earnings release and volume pick-up for confirmation. For traders, the current move offers a tactical entry with tight risk management. For longer-term investors, improvement in profitability or clearer guidance will be required before upgrading the stance beyond a HOLD.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.